LAVA Medtech Acquisition Corp.
We intend to focus our investment efforts on industries that complement our management team’s background within healthcare and healthcare-related industries, primarily in the United States and Canada. Specifically, we intend to prioritize innovative, development- or early commercial-stage companies focused on clinically-impactful and high growth opportunities within medical devices, diagnostics, and digital health (comprehensively referred to as “MedTech”), which we believe are opportunity-rich, but somewhat overlooked areas relative to the strategies of most other blank check companies currently outstanding, particularly those focused on the healthcare sector.
(Note: LAVA Medtech Acquisition Corp. priced its SPAC IPO on Oct. 26, 2021, in sync with the terms in its prospectus: 10 million units at $10 each to raise $100 million.)
|Address||303 Wyman Street, Suite 300 Waltham, Massachusetts 02451|
|View Prospectus:||LAVA Medtech Acquisition Corp.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$0 mil (last 12 months)|
|Price range||$10.00 - $10.00|
|Est. $ Volume||$100.0 mil|
|Manager / Joint Managers||RBC Capital Markets|
|Expected To Trade:||10/27/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|